ICH指导原则《S12:基因治疗产品的生物分布研究》(step 3征求意见)

2021-08-11 国家药品监督管理局药品审评中心(CDE) CDE

ICH指导原则《S12:基因治疗产品的生物分布研究》现进入第3阶段征求意见。按照ICH相关章程要求,ICH监管机构成员需收集本地区关于第2b阶段指导原则草案的意见并反馈ICH。

中文标题:

ICH指导原则《S12:基因治疗产品的生物分布研究》(step 3征求意见)

发布日期:

2021-08-11

简要介绍:

 ICH指导原则《S12:基因治疗产品的生物分布研究》现进入第3阶段征求意见。按照ICH相关章程要求,ICH监管机构成员需收集本地区关于第2b阶段指导原则草案的意见并反馈ICH。
       S12草案的原文和译文见附件,现就该指导原则及中文翻译稿向社会公开征求意见。

原始英文见:【英文】ICH_S12_Step2_DraftGuideline.pdf

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=319e51c002163e18, title= ICH指导原则《S12:基因治疗产品的生物分布研究》(step 3征求意见), enTitle=, guiderFrom=CDE, authorId=0, author=, summary= ICH指导原则《S12:基因治疗产品的生物分布研究》现进入第3阶段征求意见。按照ICH相关章程要求,ICH监管机构成员需收集本地区关于第2b阶段指导原则草案的意见并反馈ICH。, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心(CDE), associationIntro=国家药品监督管理局药品审评中心(CDE), copyright=0, guiderPublishedTime=Wed Aug 11 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>&nbsp;ICH指导原则《S12:基因治疗产品的生物分布研究》现进入第3阶段征求意见。按照ICH相关章程要求,ICH监管机构成员需收集本地区关于第2b阶段指导原则草案的意见并反馈ICH。<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S12草案的原文和译文见附件,现就该指导原则及中文翻译稿向社会公开征求意见。</p> <p>原始英文见:<a href="http://www.cde.org.cn/attachmentout.do?mothed=list&amp;id=53e6baa25a60f41a">【英文】ICH_S12_Step2_DraftGuideline.pdf</a></p>, tagList=[TagDto(tagId=1542, tagName=基因治疗)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1542, guiderKeyword=基因治疗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=10, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2489, appHits=39, showAppHits=0, pcHits=500, showPcHits=2450, likes=0, shares=4, comments=9, approvalStatus=1, publishedTime=Sat Aug 28 20:35:20 CST 2021, publishedTimeString=2021-08-11, pcVisible=1, appVisible=1, editorId=4754896, editor=小小医者, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=小小医者, createdTime=Sat Aug 28 20:35:15 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 20:05:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079597, encodeId=784a10e959798, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2d65095108, createdName=137*****173<手机用户>, createdTime=Mon Dec 13 16:14:15 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012553, encodeId=25ed1012553d1, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7ba5559227, createdName=ms5000000287314931, createdTime=Sun Aug 29 13:54:52 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012534, encodeId=81b81012534e4, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a2c5479093, createdName=ms4000001350683783, createdTime=Sun Aug 29 12:09:38 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012439, encodeId=928a101243914, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ab5545752, createdName=ms5000000668334664, createdTime=Sun Aug 29 01:02:29 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012418, encodeId=6e4b1012418fe, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Aug 28 22:57:36 CST 2021, time=2021-08-28, status=1, ipAttribution=)]
    2021-12-13 137*****173<手机用户>

    棒棒哒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1079597, encodeId=784a10e959798, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2d65095108, createdName=137*****173<手机用户>, createdTime=Mon Dec 13 16:14:15 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012553, encodeId=25ed1012553d1, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7ba5559227, createdName=ms5000000287314931, createdTime=Sun Aug 29 13:54:52 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012534, encodeId=81b81012534e4, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a2c5479093, createdName=ms4000001350683783, createdTime=Sun Aug 29 12:09:38 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012439, encodeId=928a101243914, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ab5545752, createdName=ms5000000668334664, createdTime=Sun Aug 29 01:02:29 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012418, encodeId=6e4b1012418fe, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Aug 28 22:57:36 CST 2021, time=2021-08-28, status=1, ipAttribution=)]
    2021-08-29 ms5000000287314931

    很不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1079597, encodeId=784a10e959798, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2d65095108, createdName=137*****173<手机用户>, createdTime=Mon Dec 13 16:14:15 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012553, encodeId=25ed1012553d1, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7ba5559227, createdName=ms5000000287314931, createdTime=Sun Aug 29 13:54:52 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012534, encodeId=81b81012534e4, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a2c5479093, createdName=ms4000001350683783, createdTime=Sun Aug 29 12:09:38 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012439, encodeId=928a101243914, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ab5545752, createdName=ms5000000668334664, createdTime=Sun Aug 29 01:02:29 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012418, encodeId=6e4b1012418fe, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Aug 28 22:57:36 CST 2021, time=2021-08-28, status=1, ipAttribution=)]
    2021-08-29 ms4000001350683783

    积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1079597, encodeId=784a10e959798, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2d65095108, createdName=137*****173<手机用户>, createdTime=Mon Dec 13 16:14:15 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012553, encodeId=25ed1012553d1, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7ba5559227, createdName=ms5000000287314931, createdTime=Sun Aug 29 13:54:52 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012534, encodeId=81b81012534e4, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a2c5479093, createdName=ms4000001350683783, createdTime=Sun Aug 29 12:09:38 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012439, encodeId=928a101243914, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ab5545752, createdName=ms5000000668334664, createdTime=Sun Aug 29 01:02:29 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012418, encodeId=6e4b1012418fe, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Aug 28 22:57:36 CST 2021, time=2021-08-28, status=1, ipAttribution=)]
    2021-08-29 ms5000000668334664

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1079597, encodeId=784a10e959798, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2d65095108, createdName=137*****173<手机用户>, createdTime=Mon Dec 13 16:14:15 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012553, encodeId=25ed1012553d1, content=很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7ba5559227, createdName=ms5000000287314931, createdTime=Sun Aug 29 13:54:52 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012534, encodeId=81b81012534e4, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a2c5479093, createdName=ms4000001350683783, createdTime=Sun Aug 29 12:09:38 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012439, encodeId=928a101243914, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ab5545752, createdName=ms5000000668334664, createdTime=Sun Aug 29 01:02:29 CST 2021, time=2021-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012418, encodeId=6e4b1012418fe, content=学习了,谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Aug 28 22:57:36 CST 2021, time=2021-08-28, status=1, ipAttribution=)]
    2021-08-28 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

拓展阅读

2018 专家共识:儿童接受嵌合抗原受体T细胞治疗管理指南

国外血液科相关专家小组 · 2018-08-02

基因治疗产品药学研究与评价技术指导原则(征求意见稿)

国家药品监督管理局药品审评中心(CDE) · 2020-09-14

基因治疗产品非临床研究与评价技术指导原则(征求意见稿)

国家药品监督管理局药品审评中心(CDE) · 2021-02-10

基因治疗产品长期随访临床研究技术指导原则(征求意见稿)

国家药品监督管理局药品审评中心(CDE) · 2021-06-04

FDA指导原则:细胞和基因治疗的早期临床试验中研究多形态问题

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2021-10-01

FDA指导原则:细胞和基因治疗产品早期临床试验设计的考虑

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2018-10-06